about
Feasibility and effectiveness of indicator condition-guided testing for HIV: results from HIDES I (HIV indicator diseases across Europe study)A new multidisciplinary home care telemedicine system to monitor stable chronic human immunodeficiency virus-infected patients: a randomized study[Indicator condition guided human immunodeficiency virus requesting in primary health care: results of a collaboration].Increased alpha-defensins 1-3 production by dendritic cells in HIV-infected individuals is associated with slower disease progressionEffect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards.Differential microRNA expression profile between stimulated PBMCs from HIV-1 infected elite controllers and viremic progressors.Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation.A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication.Alternative effector-function profiling identifies broad HIV-specific T-cell responses in highly HIV-exposed individuals who remain uninfected.Lymphoid tissue collagen deposition in HIV-infected patients correlates with the imbalance between matrix metalloproteinases and their inhibitorsA therapeutic dendritic cell-based vaccine for HIV-1 infection.HIV-1 Reservoir Dynamics after Vaccination and Antiretroviral Therapy Interruption Are Associated with Dendritic Cell Vaccine-Induced T Cell Responses.Rate and predictors of non-AIDS events in a cohort of HIV-infected patients with a CD4 T cell count above 500 cells/mm³.Therapeutic vaccines against HIV infection.Dendritic cell based vaccines for HIV infection: the way ahead.Safety and immunogenicity of a modified vaccinia Ankara-based HIV-1 vaccine (MVA-B) in HIV-1-infected patients alone or in combination with a drug to reactivate latent HIV-1.Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar age and from the same geographical area.Early Detection Of Hiv Infection And Of Asymptomatic Sexually Transmitted Infections Among Men Who Have Sex With Men.Immunological function restoration with lopinavir/ritonavir versus efavirenz containing regimens in HIV-infected patients: a randomized clinical trialA randomized clinical trial comparing ritonavir-boosted lopinavir versus maraviroc each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.A randomized clinical trial comparing ritonavir-boosted lopinavir versus raltegravir each with tenofovir plus emtricitabine for post-exposure prophylaxis for HIV infection.Analysis of Non-AIDS-Defining Events in HIV Controllers.Assessment of migration of HIV-1-loaded dendritic cells labeled with 111In-oxine used as a therapeutic vaccine in HIV-1-infected patients.Predictive Factors for HIV Seroconversion Among Individuals Attending a Specialized Center After an HIV Risk Exposure: A Case-Control Study.Adenosine deaminase regulates Treg expression in autologous T cell-dendritic cell cocultures from patients infected with HIV-1.Detection of HIV-1-specific T-cell immune responses in highly HIV-exposed uninfected individuals by in-vitro dendritic cell co-culture.Association of microbial translocation biomarkers with clinical outcome in controllers HIV-infected patients.Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients.Reasons for not participating in a phase 1 preventive HIV vaccine study in a resource-rich country.Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir.Influence of repeated cycles of structured therapy interruption on the rate of recovery of CD4+ T cells after highly active antiretroviral therapy resumption.Gynecomastia among HIV-infected patients is associated with hypogonadism: a case-control study.Zidovudine/lamivudine/abacavir plus tenofovir in HIV-infected naive patients: a 96-week prospective one-arm pilot study.Evolution of resistance mutations pattern in HIV-1-infected patients during intensification therapy with a boosted protease inhibitor.Role of APOBEC3H in the Viral Control of HIV Elite Controller Patients.Comparison of two HIV testing strategies in primary care centres: indicator-condition-guided testing vs. testing of those with non-indicator conditions.Intrathoracic fat in HIV-infected patients.Ex vivo production of autologous whole inactivated HIV-1 for clinical use in therapeutic vaccinesAntiretroviral activity of didanosine in patients with different clusters of reverse transcriptase mutations
P50
Q28485122-AEAE16A1-27DA-4896-A502-F4BAF82D40AEQ28743362-4FCEA981-4483-49B5-B888-E5284203C1E7Q33421199-D2DA4E1C-31A9-4D2F-BDFB-248FA373099AQ33535953-E66DFF20-D842-4FC6-8E99-BFB9687A89B2Q33564972-AAFE3F0D-34A3-48D9-842A-BCEC6CD204DCQ34194608-1E3364C5-2BD3-4321-A235-63E07447A043Q34288534-A5226DA6-2DF9-4EE9-B084-D7E74EDD12C0Q34646987-B9E413F6-FF96-4EE5-83AE-E1E0796C118EQ34664829-64EC452F-27CD-49F9-87F1-A4403FF32839Q34764052-6730C7E8-D35C-456A-BA44-AA71BA0C6818Q34764392-C5CCC230-CEFA-4D9C-9798-38496E5FC1D2Q35973632-94EA53D8-3FF1-4EDD-A695-BDC081ECCEFAQ37025746-54EF3BF5-0D49-44B2-BD57-40F6178EE52BQ38013505-46EACE6C-AC86-420D-9735-2333D7672E4DQ38126373-FC8DD9FD-9E77-4E09-94CC-F834B3CAD1DFQ38415577-386B4E18-E6B5-4DC2-A76B-2C7CD718AA88Q38462726-8C061055-A1D5-4639-9C67-5FF5BD6C8B5DQ38607131-FE53C84D-62F0-4F8A-BA03-4EF313091B0EQ39230042-468461A3-6E41-4D23-8D48-D3F6DFCB4115Q39905748-57B9E27D-D52C-4CC4-A75C-3187DD367CEAQ39905759-EE02672B-6746-4B9A-91B1-CC5D592348D7Q39952253-B0B13739-D1F9-4D43-9B27-EF04807D1668Q39984018-0AE54D68-6A60-4B86-BC2D-2FBD024073D6Q40600144-51D278BD-A298-4278-BC53-779B8BDFBCABQ41031764-FE22EF5C-E7B2-4C04-8C14-C55CCE2DC229Q41150458-13045B49-99DF-49DF-A1C8-6CC8867A568AQ41350252-6ECF0F7A-0040-40F6-8767-B060E3500009Q43033610-F7F4CAC4-1D89-46A0-A2D4-DE25F07166B1Q43408598-C1BEFB80-D40E-4761-B9F4-57060076F391Q43674656-15BE1C5C-D305-4129-BECB-3875027A8CB6Q44807945-410C8F60-F34C-4388-8423-AEE329AF3706Q44948765-42D76EC6-D938-4D01-9525-C58C76788F4CQ45152103-9EF53384-D925-428E-9BD9-EF7F60DD3DEFQ46451700-9B763E2A-69C0-4EB2-AAE1-5D59696C6488Q46469229-B3244025-E5C1-47C1-8C70-C046150A01C8Q47553808-409481D1-F516-424B-B673-8DE37E9B1783Q51781116-3AB2A1D1-1251-4970-A656-76A0306714FDQ53762515-7824F79B-E54E-4A19-A149-F6390752A8EDQ56791508-F0788467-95FE-494A-B4CB-68182D8138CBQ56791533-EBFBC914-89A3-447B-8262-B297382B61FD
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Agathe León
@ast
Agathe León
@en
Agathe León
@es
Agathe León
@nl
type
label
Agathe León
@ast
Agathe León
@en
Agathe León
@es
Agathe León
@nl
prefLabel
Agathe León
@ast
Agathe León
@en
Agathe León
@es
Agathe León
@nl
P106
P21
P31
P496
0000-0002-1198-5090